Advertisement: Why this emerging industry is giving society a new lease on life

Posted by:


  • The opioid epidemic has become a worldwide crisis, with more than 130 people dying every day from an overdose in the U.S. alone
  • It’s not just the addict who’s affected. It’s their family and friends as well – and communities
  • Universal Ibogaine Inc. has a plan to curb the number of opioid-related deaths through its plant-based treatment approach

North America has been ravaged by the opioid crisis with people unknowingly consuming highly potent and dangerous substances legally prescribed. This has led to a rise in overdoses — currently, the number one reason people are dying under 50. The volume of medical emergencies in Vancouver’s Eastside alone would be a significant cause for concern, but the problem extends across all of Canada and the U.S.

Between 2016 and June 2019, over a quarter of the 4,559 overdose deaths in B.C. occurred in Vancouver, the hardest-hit city in Canada. Opioid overdoses do not discriminate either — the epidemic has affected regular white-collar and blue-collar individuals, not just those on the fringes of society.

Opioid overdoses have become all too commonplace in North America and many, including the National Institute on Drug Abuse, have pointed to the pharmaceutical industry as being a big part of the problem. According to the Institute, “In the late 1990’s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers, [so] healthcare providers began to prescribe them at greater rates.”

They go on to explain that this “subsequently led to widespread diversion and misuse of these medications before it became clear that these medications could indeed be highly addictive.” It is fair to say that opioid addiction is the first legally created epidemic.

The rise in opioid-related overdoses from 1999-2017. Sourced from the CDC.


In 2018, an estimated 10.3 million Americans aged 12 and older misused opioids, “including 9.9 million prescription pain relief abusers and 808,000 heroin users.” The fact that Americans under the age of 18 are included in these statistics is heartbreaking — children should not be anywhere near opioids, and it’s disquieting that minors can be users too.

Fentanyl is the worst of the opioids, it’s the one that has the most overdose deaths. The problem with addiction, especially with opioids is that it doesn’t just affect the user. It affects everything around that person — their family, their work, and society itself.

Dr. Alberto Sola, CEO, Universal Ibogaine Inc.

Further to Dr. Sola’s point, he’s right in noting that it’s not just the user who is afflicted by the addiction. Most often, “family and friends uncomfortably watch their loved ones transform in harmful ways.” Family members, coworkers, and friends also endure difficult situations at home as their mothers, daughters, sons, uncles, aunts, or best friends go through insurmountable pain.

Parents can even lose their children to the streets as they are driven to engage in this harmful behaviour, a behaviour that could potentially take away their lives. Families might even carry the burden that it’s their fault and their responsibility to rectify their loved one’s situation, but this often remains out of their control.

Families often carry the burden of their loved one’s addiction, and it puts a lot of stress on the household.


The addictive properties of opioids such as heroin, morphine, and fentanyl can pose serious adverse effects for users because they are synthetically made. According to the United States Drug Enforcement Agency (DEA), fentanyl is 80–100 times stronger than morphine. It’s also 50 times more potent than heroin.

The DEA also explains that “pharmaceutical fentanyl was developed for pain management,” for instance in the use of cancer treatment, but “because of its powerful opioid properties, [the substance] is also diverted for abuse.”

Revolutionary crisis control for opioids

Shayne Nyquvest, Founder of Universal Ibogaine, Inc., explains that with the strength of drugs today, addicts have no chance of getting through detox without clinical and medical assistance. Universal Ibogaine will play a crucial role in combatting the opioid crisis by tackling addiction treatment through a revolutionary, all-natural, plant-based approach that begins with detox which carries on through rehabilitation treatment.

The company has turned to ibogaine, a psychoactive substance found mostly in the root bark of the iboga plant. This plant has been used for medicinal purposes in African spiritual traditions for decades. The company believes, and multiple data sources recount that ibogaine has shown positive effects in decreasing withdrawal symptoms in addicts.

Universal Ibogaine is a Canadian company that operates the Clear Sky Addictions Solutions clinic with a safe and effective seven-day treatment using ibogaine, all while changing attitudes towards vibrant new medical solutions.


Nyquvest explains how Clear Sky Addictions Solutions, “is nothing short of phenomenal.” He adds, “The clinic involves a better after-care system that involves life coaches, and a glass-half-full approach.” One of the other benefits of this clinic is that it is located in Cancun, so its treatment protocol is in a warm and relaxing atmosphere.

A critical mandate for changeis a necessity

Patrick Kroupa, Ibogaine Treatment Expert at Clear Sky Solutions explains that when the current success rate for conventional detox methods is at a troubling four to six per cent, the system needs to substantially change. He notes that “If you can take this current rate and increase it to a 50–60 per cent success rate, you have significantly moved the needle on the entire spectrum of problems that’s not only affecting Canada or the United States. Ibogaine is a substance that can make a significant dent in recovery.”

We have a once in a lifetime opportunity to invest in a company that helps the sufferers of a modern-day epidemic, the opioid crisis, by bringing them a safe and effective, seven-day treatment with ibogaine. It’s an opportunity to save lives, change paradigms in the addiction industry and pioneer a brand-new market.

Dr. Alberto Sola, CEO, Universal Ibogaine Inc.

Clear Sky Solutions’ use of ibogaine has been hailed as a promising alternative for people seeking help, and their clinic in Cancun helped Liz, a patient who stayed at the facility for 19 days, turn her life around.

She explains, “We come here because we don’t know where else to go. This is the best place that I’ve ever found and if I ever needed treatment again, I would come back here. It’s a safe place.”

Chris, another patient, reinforces this notion and says he decided to come to Cancun to seek alternative methods to cure his addiction. He explains that he had heard about ibogaine a couple of times and after doing some research it seemed like the right course of action.

“Upon arrival, everything was wonderful. They make sure you’re comfortable. You really feel like you’re at home. It’s a full medical staff, and this is the best place as far as I’m concerned. They tell you what you expect and what not to expect.”

More testimonials from Clear Sky Recovery can be found here.

Ibogaine is gaining popularity among investors

While Dr. Sola, Shayne Nyquvest, and Patrick Kroupa are all commending ibogaine’s benefits, it’s important to understand how the plant actually works. Ibogaine is a psychoactive substance found in the iboga plant, and it’s also part of a growing industry already worth around $200 million in investments, according to the 2020 Psychedelic Insight Report. The plant is also extremely beneficial because:

  • It is extremely fast-acting
  • It is plant-based and naturally occurring

In turn, the growing psychedelics industry has caught the attention of biotech investors who believe that psychedelics are part of the next wave of treatments to remedy the opioid epidemic. According to the Multidisciplinary Association for Psychedelic Studies (MAPS), the U.S. Food and Drug Administration (FDA), gave life sciences start-up COMPASS Pathways, a “Breakthrough Therapy” designation for its research into psilocybin (an active ingredient in magic mushrooms) for depression, allowing legal clinical trials to start.

Many researchers are projecting that magic mushrooms could replace traditional antidepressants in as little as five years. This is welcoming news, as over 300 million people worldwide suffer from mental illness, according to the World Health Organization. With all of this arsenal in their back pocket, Universal Ibogaine has built up a strong investment case for its stakeholders.

Mushrooms (a main type of psychedelic) are a high-quality source of nutrition and protein.


The company is entering the next multi-billion-dollar industry and its mission is coming to fruition as they have already provided 3,400 treatments with their enhanced safety protocols. They will also be undertaking clinical trials in Canada later this year, with a TSX Venture listing on the horizon as well. And, by 2025, the company is projecting over 23,000 patients.

Dr. Sola puts the company’s goals well, “We have a once in a lifetime opportunity to invest in a company that helps the sufferers of a modern-day epidemic, the opioid crisis, by bringing them a safe and effective, seven-day treatment with ibogaine. It’s an opportunity to save lives, change paradigms in the addiction industry and pioneer a brand-new market.”

Clear Sky Addictions Solutions is offering a bold new treatment for opioid use disorder. The clinics are established in low-cost jurisdictions, minimizing expenditures and increasing return-on-investment for shareholders.

Together the team is reverently looking for alternatives to conventional prescription pills. They are determined to act on an issue that has plagued thousands of individuals worldwide. While nearly 100 cities across the U.S. are creating legislation to decriminalize psychedelics and multiple U.S. jurisdictions have passed decriminalization, federal changes will still be required to open legal markets to the full potential to create impactful changes.

According to the 2020 Psychedelic Insights Report, “With Universal Ibogaine taking ibogaine through the Canadian clinical process and the grassroots support from Health Canada, ibogaine will be the first psychedelic approach available to consumers. Although ibogaine is still a scheduled drug in the U.S. and some European jurisdictions, it is not scheduled in Canada and the majority of the global market, so there is a lot of promise for this substance.”

For more information about Universal Ibogaine and its successful Clear Sky Addiction Solutions clinic, visit the company’s website here.

Universal Ibogaine is providing investors with a bold new investment opportunity to help combat the opioid epidemic. Backed by a knowledgeable management team and operating clinic in Cancun, the company is now financing at $0.10 a common share.

To learn more about how you can participate in the company’s financing, click here.

This story was provided by Market One Media Group for commercial purposes.


Source link